XML 69 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Fair Value - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2020
Jan. 31, 2016
Dec. 31, 2020
Dec. 31, 2019
Oct. 27, 2020
Feb. 28, 2018
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Change in contingent consideration     $ 818 $ 4,114    
Put option liability     $ 3,400 3,261    
Warrant, exercise price     $ 4.46      
Warrants, expires period     Feb. 23, 2028      
Estimated air value of warrants issued     $ 300      
Warrant issued to purchase shares     103,326      
Increase in value of the warrant liability     $ 1,252 $ 104    
Initial Public Offering            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Warrant, exercise price     $ 4.46      
Warrant issued to purchase shares     103,326   103,326  
Series F Preferred Stock            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Contingent value rights shares   3,999        
Contingent value rights   $ 500        
Contingent value rights percentage   0.00375%        
Net proceeds percentage of cash payment to the CVR holders   15.00%        
Series F Preferred Stock | AVEO Oncology            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Percentage of development and regulatory costs exercised using opt-out right 50.00%          
2018 Notes            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Estimated air value of warrants issued           $ 300
2018 Notes | Series G Preferred Stock            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Warrant issued to purchase shares     613,333     613,333
Warrant, exercise price     $ 0.75      
Minimum            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range     12.20%      
Maximum            
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range     13.50%